Northeast Pharmaceutical Group Management

Management Kriterienprüfungen 3/4

Northeast Pharmaceutical Group's CEO ist Zhou Kai, ernannt in May 2019, hat eine Amtszeit von 3.5 Jahren. besitzt direkt 0.3% der Aktien des Unternehmens, im Wert von CN¥18.86M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.2 Jahre bzw. 4.5 Jahre.

Wichtige Informationen

Zhou Kai

Geschäftsführender

CN¥1.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	5.1yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.6yrs

Jüngste Management Updates

Recent updates

These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

May 25

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Apr 05

Geschäftsführer

Zhou Kai (60 yo)

5.1yrs

Amtszeit

CN¥1,824,100

Vergütung

Mr. Zhou Kai serves as a General Manager of Northeast Pharmaceutical Group Co., Ltd. since May 8, 2019 and serves its Non-Independent Director since November 29, 2020. He served as a Vice President of Nort...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Zhou Kai	GM & Director	5.1yrs	CN¥1.82m	0.30% CN¥ 16.3m
Jialun Song	Financial Director & Secretary	1.3yrs	CN¥2.14m	0.022% CN¥ 1.2m
Xiao Feng	Deputy General Manager	less than a year	CN¥894.30k	keine Daten
Wei Zheng	Deputy General Manager	3.3yrs	CN¥890.90k	0.077% CN¥ 4.2m

2.3yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: 000597Das Führungsteam des Unternehmens gilt als erfahren (2.2 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Zhou Kai	GM & Director	3.6yrs	CN¥1.82m	0.30% CN¥ 16.3m
Demin Han	Independent Director	5.9yrs	CN¥150.00k	keine Daten
Zhaochun Tan	Non-Independent Director	2.6yrs	keine Daten	keine Daten
Chengren Huang	Non-Independent Director	5.9yrs	keine Daten	0.23% CN¥ 12.5m
Xinhua Ao	Non-Independent Director	5.9yrs	keine Daten	0.23% CN¥ 12.5m
Guodong Wang	Independent Director	5.9yrs	CN¥150.00k	keine Daten
Hui Yao	Independent Director	5.9yrs	CN¥150.00k	keine Daten
Youguang Shang	Independent Director	3.7yrs	CN¥150.00k	keine Daten
Jianmin Guo	Chairman of the Board	2.7yrs	CN¥2.07m	0.22% CN¥ 12.4m
Zhihua Huang	Non-Independent Director	2.6yrs	keine Daten	0.070% CN¥ 3.9m
Baidan Zhan	Chairman of the Supervisory Board	5.5yrs	keine Daten	keine Daten
Hai Tian	Director	less than a year	keine Daten	keine Daten

4.6yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: 000597Die Vorstandsmitglieder gelten als erfahren (4.5 Jahre durchschnittliche Amtszeit).

Northeast Pharmaceutical Group Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Recent updates

These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

Dividend of CN¥0.10 announced

Northeast Pharmaceutical Group Co., Ltd. Implements 2023 Final Cash Profit Distribution Plan, Payable on 23 May 2024

New minor risk - Earnings quality

First quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.049 in 1Q 2023)

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Full year 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in FY 2022)

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment deteriorates as stock falls 18%

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

High number of new directors

Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.033 in 2Q 2022)

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. Announces 2022 Final Cash Profit Distribution Plan, Payable on 16 May 2023

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.07 in FY 2021)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.026 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.016 in 2Q 2021)

High number of new directors

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2021, Payable on 27 May 2022

First quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.029 in 1Q 2021)

Northeast Pharmaceutical Group Co., Ltd. Approves the Profit Distribution for 2021

Full year 2021 earnings released: EPS: CN¥0.07 (vs CN¥0.01 in FY 2020)

Northeast Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for 2021

High number of new directors

Third quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.016 (vs CN¥0.063 in 2Q 2020)

Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend of A Shares, Payable on 27 May 2021

First quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.013 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.01 (vs CN¥0.13 in FY 2019)

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 17, 2021

New 90-day low: CN¥4.86

New 90-day low: CN¥5.03

New 90-day low: CN¥5.37

New 90-day low: CN¥5.39

Third quarter earnings released

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jiangxi Fangda Steel Technology Co., Ltd. completed the acquisition of an additional 10% stake in Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) for approximately CNY 890 million.

Northeast Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 2 billion in funding from Joyvio Group Co., Ltd., Liaoning Fangda Group Industrial Co., Ltd., and other investors

First half earnings released

New 90-day high - CN¥6.15

New 90-day high - CN¥6.02

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter